Cohance Life

{
  "main_header": {
    "sid": 1003386,
    "name": "Cohance Life",
    "stock_name": "Cohance Life",
    "full_name": "Cohance Lifesciences Ltd",
    "name_url": "stocks-analysis/cohance-life",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "488.20",
    "chg": 3.35,
    "chgp": "0.69%",
    "dir": 1,
    "prev_price": "484.85",
    "mcapval": "18,794.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543064,
    "symbol": "COHANCE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE03QK01018",
    "curr_date": "May 08",
    "curr_time": "",
    "bse_nse_vol": "27.27 lacs",
    "exc_status": "Active",
    "traded_date": "May 08, 2026",
    "traded_date_str": "2026 05 08",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cohance-life-1003386-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Cohance Lifesciences Gains 3.90%: 4 Key Factors Driving This Week's Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-gains-390-4-key-factors-driving-this-weeks-momentum-3983087",
        "imagepath": "",
        "date": "2026-05-09 12:02:54",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>4 May:</strong> Week opens at Rs.469.95</p>\n                    <p><strong>5 May:</strong> Stock declines 3.27% amid moderate market dip</p>\n                    <p><strong>6 May:</strong> Intraday high surge to Rs.498.05 with 8.78% rally and heavy value trading</p>\n                    <p><strong>7 May:</strong> Continued gains with 0.82% rise and strong volume</p>\n                    <p><strong>8 May:</strong> Modest 0.70% gain amid mixed technical momentum</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.469.95</div></div>\n                    <div class=..."
      },
      {
        "title": "Cohance Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-technical-momentum-shifts-amid-mixed-market-signals-3980825",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_technicaldot_3980825.png",
        "date": "2026-05-08 08:05:10",
        "description": "Cohance Lifesciences Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a modest day gain of 0.82%, the stock remains under pressure with a MarketsMOJO Mojo Score of 38.0 and a Sell grade, signalling cautious investor sentiment amid volatile market conditions."
      },
      {
        "title": "When is the next results date for Cohance Lifesciences Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-cohance-lifesciences-ltd-3980479",
        "imagepath": "",
        "date": "2026-05-07 23:17:14",
        "description": "Cohance Lifesciences Ltd is scheduled to declare its results on 12 May 2026...."
      },
      {
        "title": "Cohance Lifesciences Ltd Sees Surge in Value Trading Amid Sector Outperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-sees-surge-in-value-trading-amid-sector-outperformance-3977434",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_most_active_equities_by_value_3977434.png",
        "date": "2026-05-06 10:00:27",
        "description": "Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge in trading activity on 6 May 2026, driven by high-value turnover and notable institutional interest. The stock outperformed its sector and broader market indices, signalling renewed investor confidence despite a recent downgrade in its mojo grade."
      },
      {
        "title": "Cohance Lifesciences Ltd Surges 8.78% to Day's High of Rs 498.05 — Outperforms Sector by 8.05 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-hits-intraday-high-with-strong-878-surge-3977263",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_priceRelatedfactors_3977263.png",
        "date": "2026-05-06 09:31:11",
        "description": "The Sensex gained a modest 0.52% on 6 May 2026, while Cohance Lifesciences Ltd surged 8.78%, reaching an intraday high of Rs 498.05. This 8.05-percentage-point outperformance over its Pharmaceuticals &amp; Biotechnology sector peers highlights a distinctly stock-specific rally rather than a broad market lift."
      },
      {
        "title": "Cohance Lifesciences Ltd Valuation Shifts Signal Price Attractiveness Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-valuation-shifts-signal-price-attractiveness-challenges-3976748",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_valuationdot_3976748.png",
        "date": "2026-05-06 08:00:55",
        "description": "Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, prompting a reassessment of its price attractiveness. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers and historical averages raise questions about its investment appeal amid volatile market returns."
      },
      {
        "title": "Cohance Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cohance-lifesciences-ltd-is-rated-sell-3972802",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_mojoScore_3972802.png",
        "date": "2026-05-03 10:10:36",
        "description": "Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Jan 2026. However, the analysis below reflects the stock's current position as of 03 May 2026, incorporating the latest fundamentals, returns, and financial metrics to provide investors with an up-to-date perspective."
      },
      {
        "title": "Cohance Lifesciences Surges 33.93% in a Week: Key Drivers and Valuation Risks",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-surges-3393-in-a-week-key-drivers-and-valuation-risks-3971469",
        "imagepath": "",
        "date": "2026-05-02 12:02:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>27 Apr:</strong> Upper circuit hit with 19.99% surge and record volume</p>\n                    <p><strong>28 Apr:</strong> Intraday high of Rs.488 and heavy institutional buying</p>\n                    <p><strong>29 Apr:</strong> Valuation shifts raise price risk concerns amid 14.20% gain</p>\n                    <p><strong>30 Apr:</strong> Moderate recovery to close at Rs.482.95 (+3.22%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.360.60</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-va..."
      },
      {
        "title": "Cohance Lifesciences Ltd Valuation Shifts Signal Heightened Price Risk Amid Sector Comparisons",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-valuation-shifts-signal-heightened-price-risk-amid-sector-comparisons-3967395",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/CohanceLifescie_valuationdot_3967395.png",
        "date": "2026-04-29 08:00:50",
        "description": "Cohance Lifesciences Ltd has witnessed a significant shift in its valuation parameters, moving from an already expensive rating to a very expensive classification. This change, coupled with a sharp 14.2% surge in its share price on 29 Apr 2026, invites a detailed analysis of its price attractiveness relative to historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 558,
    "sid": "1003386",
    "stock_news_url": "https://www.marketsmojo.com/news/cohance-lifesciences-1003386"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "12 May 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cohance Lifesciences Ltd has declared <strong>100%</strong> dividend, ex-date: 09 Sep 22",
          "dt": "2022-09-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cohance Lifesciences Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 25 Sep 20",
          "dt": "2020-09-25",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Cohance Lifesciences Gains 3.90%: 4 Key Factors Driving This Week's Momentum

2026-05-09 12:02:54

Key Events This Week

4 May: Week opens at Rs.469.95

5 May: Stock declines 3.27% amid moderate market dip

6 May: Intraday high surge to Rs.498.05 with 8.78% rally and heavy value trading

7 May: Continued gains with 0.82% rise and strong volume

8 May: Modest 0.70% gain amid mixed technical momentum

Week Open

Rs.469.95

Read full news article

Cohance Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-05-08 08:05:10

Cohance Lifesciences Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a modest day gain of 0.82%, the stock remains under pressure with a MarketsMOJO Mojo Score of 38.0 and a Sell grade, signalling cautious investor sentiment amid volatile market conditions.

Read full news article

When is the next results date for Cohance Lifesciences Ltd?

2026-05-07 23:17:14

Cohance Lifesciences Ltd is scheduled to declare its results on 12 May 2026....

Read full news article

Cohance Lifesciences Ltd Sees Surge in Value Trading Amid Sector Outperformance

2026-05-06 10:00:27

Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge in trading activity on 6 May 2026, driven by high-value turnover and notable institutional interest. The stock outperformed its sector and broader market indices, signalling renewed investor confidence despite a recent downgrade in its mojo grade.

Read full news article

Cohance Lifesciences Ltd Surges 8.78% to Day's High of Rs 498.05 — Outperforms Sector by 8.05 Percentage Points

2026-05-06 09:31:11

The Sensex gained a modest 0.52% on 6 May 2026, while Cohance Lifesciences Ltd surged 8.78%, reaching an intraday high of Rs 498.05. This 8.05-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a broad market lift.

Read full news article

Cohance Lifesciences Ltd Valuation Shifts Signal Price Attractiveness Challenges

2026-05-06 08:00:55

Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, prompting a reassessment of its price attractiveness. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers and historical averages raise questions about its investment appeal amid volatile market returns.

Read full news article

Cohance Lifesciences Ltd is Rated Sell

2026-05-03 10:10:36

Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Jan 2026. However, the analysis below reflects the stock's current position as of 03 May 2026, incorporating the latest fundamentals, returns, and financial metrics to provide investors with an up-to-date perspective.

Read full news article

Cohance Lifesciences Surges 33.93% in a Week: Key Drivers and Valuation Risks

2026-05-02 12:02:04

Key Events This Week

27 Apr: Upper circuit hit with 19.99% surge and record volume

28 Apr: Intraday high of Rs.488 and heavy institutional buying

29 Apr: Valuation shifts raise price risk concerns amid 14.20% gain

30 Apr: Moderate recovery to close at Rs.482.95 (+3.22%)

Week Open

Rs.360.60

Week Close

Read full news article

Cohance Lifesciences Ltd Valuation Shifts Signal Heightened Price Risk Amid Sector Comparisons

2026-04-29 08:00:50

Cohance Lifesciences Ltd has witnessed a significant shift in its valuation parameters, moving from an already expensive rating to a very expensive classification. This change, coupled with a sharp 14.2% surge in its share price on 29 Apr 2026, invites a detailed analysis of its price attractiveness relative to historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News